These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 19562573)

  • 1. Pulse pressure, left ventricular function and cardiovascular events during antihypertensive treatment (the LIFE study).
    Gerdts E; Franklin S; Rieck A; Papademetriou V; Wachtell K; Nieminen M; Dahlöf B; Devereux RB
    Blood Press; 2009; 18(4):180-6. PubMed ID: 19562573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gender differences in left ventricular structure and function during antihypertensive treatment: the Losartan Intervention for Endpoint Reduction in Hypertension Study.
    Gerdts E; Okin PM; de Simone G; Cramariuc D; Wachtell K; Boman K; Devereux RB
    Hypertension; 2008 Apr; 51(4):1109-14. PubMed ID: 18259011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Higher pulse pressure/stroke volume index is associated with impaired outcome in hypertensive patients with left ventricular hypertrophy the LIFE study.
    Mancusi C; Gerdts E; de Simone G; Midtbø H; Lønnebakken MT; Boman K; Wachtell K; Dahlöf B; Devereux RB
    Blood Press; 2017 Jun; 26(3):150-155. PubMed ID: 27710139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of diabetes on treatment-induced changes in left ventricular structure and function in hypertensive patients with left ventricular hypertrophy. The LIFE study.
    Gerdts E; Okin PM; Omvik P; Wachtell K; Dahlöf B; Hildebrandt P; Nieminen MS; Devereux RB
    Nutr Metab Cardiovasc Dis; 2009 Jun; 19(5):306-12. PubMed ID: 19303268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In-treatment stroke volume predicts cardiovascular risk in hypertension.
    Lønnebakken MT; Gerdts E; Boman K; Wachtell K; Dahlöf B; Devereux RB
    J Hypertens; 2011 Aug; 29(8):1508-14. PubMed ID: 21720264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of isolated systolic hypertension on normalization of left ventricular structure during antihypertensive treatment (the LIFE study).
    Mancusi C; Gerdts E; De Simone G; Abdelhai YM; Lønnebakken MT; Boman K; Wachtell K; Dahlöf B; Devereux RB
    Blood Press; 2014 Aug; 23(4):206-12. PubMed ID: 24564262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of left ventricular geometry on prognosis in hypertensive patients with left ventricular hypertrophy (the LIFE study).
    Gerdts E; Cramariuc D; de Simone G; Wachtell K; Dahlöf B; Devereux RB
    Eur J Echocardiogr; 2008 Nov; 9(6):809-15. PubMed ID: 18490279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of left ventricular mass change during treatment of hypertension.
    Devereux RB; Wachtell K; Gerdts E; Boman K; Nieminen MS; Papademetriou V; Rokkedal J; Harris K; Aurup P; Dahlöf B
    JAMA; 2004 Nov; 292(19):2350-6. PubMed ID: 15547162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Left atrial size and risk of major cardiovascular events during antihypertensive treatment: losartan intervention for endpoint reduction in hypertension trial.
    Gerdts E; Wachtell K; Omvik P; Otterstad JE; Oikarinen L; Boman K; Dahlöf B; Devereux RB
    Hypertension; 2007 Feb; 49(2):311-6. PubMed ID: 17178978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Left ventricular function and hemodynamic features of inappropriate left ventricular hypertrophy in patients with systemic hypertension: the LIFE study.
    Palmieri V; Wachtell K; Gerdts E; Bella JN; Papademetriou V; Tuxen C; Nieminen MS; Dahlöf B; de Simone G; Devereux RB
    Am Heart J; 2001 May; 141(5):784-91. PubMed ID: 11320367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of hemoglobin delivery with left ventricular structure and function in hypertensive patients: Losartan Intervention for End Point Reduction in Hypertension Study.
    Narayan P; Papademetriou V; Wachtell K; Gerdts E; Boman K; Nieminen MS; de Simone G; Dahlöf B; Fyhrquist F; Hoieggen A; Devereux RB
    Hypertension; 2006 May; 47(5):868-73. PubMed ID: 16567586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of pulse pressure with new-onset atrial fibrillation in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint (LIFE) reduction in hypertension study.
    Larstorp AC; Ariansen I; Gjesdal K; Olsen MH; Ibsen H; Devereux RB; Okin PM; Dahlöf B; Kjeldsen SE; Wachtell K
    Hypertension; 2012 Aug; 60(2):347-53. PubMed ID: 22753219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exercise and cardiovascular outcomes in hypertensive patients in relation to structure and function of left ventricular hypertrophy: the LIFE study.
    Boman K; Gerdts E; Wachtell K; Dahlöf B; Nieminen MS; Olofsson M; Papademetriou V; Devereux RB
    Eur J Cardiovasc Prev Rehabil; 2009 Apr; 16(2):242-8. PubMed ID: 19369828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systolic left ventricular function according to left ventricular concentricity and dilatation in hypertensive patients: the Losartan Intervention For Endpoint reduction in hypertension study.
    Bang CN; Gerdts E; Aurigemma GP; Boman K; Dahlöf B; Roman MJ; Køber L; Wachtell K; Devereux RB
    J Hypertens; 2013 Oct; 31(10):2060-8. PubMed ID: 23838656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Left ventricular wall stresses and wall stress-mass-heart rate products in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint reduction in hypertension.
    Devereux RB; Roman MJ; Palmieri V; Okin PM; Boman K; Gerdts E; Nieminen MS; Papademetriou V; Wachtell K; Dahlöf B
    J Hypertens; 2000 Aug; 18(8):1129-38. PubMed ID: 10954006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Change of left ventricular geometric pattern after 1 year of antihypertensive treatment: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
    Wachtell K; Dahlöf B; Rokkedal J; Papademetriou V; Nieminen MS; Smith G; Gerdts E; Boman K; Bella JN; Devereux RB
    Am Heart J; 2002 Dec; 144(6):1057-64. PubMed ID: 12486431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In-treatment midwall and endocardial fractional shortening predict cardiovascular outcome in hypertensive patients with preserved baseline systolic ventricular function: the Losartan Intervention For Endpoint reduction study.
    Wachtell K; Gerdts E; Palmieri V; Olsen MH; Nieminen MS; Papademetriou V; Boman K; Dahlöf B; Aurigemma GP; Rokkedal JE; Devereux RB
    J Hypertens; 2010 Jul; 28(7):1541-6. PubMed ID: 20410835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: The LIFE Study.
    Wachtell K; Gerdts E; Aurigemma GP; Boman K; Dahlöf B; Nieminen MS; Olsen MH; Okin PM; Palmieri V; Rokkedal JE; Devereux RB
    Blood Press; 2010 Jun; 19(3):169-75. PubMed ID: 20438307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of age on left ventricular hypertrophy regression during antihypertensive treatment with losartan or atenolol (the LIFE study).
    Gerdts E; Roman MJ; Palmieri V; Wachtell K; Smith G; Nieminen MS; Dahlöf B; Devereux RB
    J Hum Hypertens; 2004 Jun; 18(6):417-22. PubMed ID: 15103312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy.
    Solomon SD; Appelbaum E; Manning WJ; Verma A; Berglund T; Lukashevich V; Cherif Papst C; Smith BA; Dahlöf B;
    Circulation; 2009 Feb; 119(4):530-7. PubMed ID: 19153265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.